Daewoong inks W145.2b Envlo export deal for MENA

Daewoong Pharmaceutical said Thursday it has signed a 145.2 billion won ($93.4 million) export and supply agreement with Switzerland-based Acino Pharma AG to launch its diabetes drug Envlo in eight major markets across the Middle East and North Africa.

The company said the deal is Envlo's largest export agreement to date and marks the first entry of a Korean-developed sodium-glucose cotransporter-2 (SGLT-2) inhibitor into the MENA market.

Under the agreement, Daewoong plans to secure marketing a ...